Literature DB >> 17985144

Reduced striatal tyrosine hydroxylase in incidental Lewy body disease.

Thomas Gerald Beach1, Charles H Adler, Lucia I Sue, Jeffrey B Peirce, Jyothi Bachalakuri, Jessica E Dalsing-Hernandez, Lih Fen Lue, John N Caviness, Donald J Connor, Marwan N Sabbagh, Douglas G Walker.   

Abstract

Incidental Lewy body disease (ILBD) is the term used when Lewy bodies are found in the nervous system of subjects without clinically documented parkinsonism or dementia. The prevalence of ILBD in the elderly population has been estimated at between 3.8 and 30%, depending on subject age and anatomical site of sampling. It has been speculated that ILBD represents the preclinical stage of Parkinson's disease (PD) and/or dementia with Lewy bodies (DLB). Studies of ILBD could potentially identify early diagnostic signs of these disorders. At present, however, it is impossible to know whether ILBD is a precursor to PD or DLB or is just a benign finding of normal aging. We hypothesized that, if ILBD represents an early stage of PD or DLB, it should be associated with depletion of striatal dopaminergic markers. Eleven subjects with ILBD and 27 control subjects were studied. The ILBD subjects ranged in age from 74 to 96 years (mean 86.5) while the control subjects' age ranged from 75 to 102 years (mean 86.7). Controls and subjects did not differ in terms of age, postmortem interval, gender distribution, medical history conditions, brain weight, neuritic plaque density or Braak neurofibrillary stage. Quantitative ELISA measurement of striatal tyrosine hydroxylase (TH), the principal enzyme for dopamine synthesis, showed a 49.8% (P = 0.01) reduction in ILBD cases, as compared with control cases. The finding suggests that ILBD is not a benign condition but is likely a precursor to PD and/or DLB.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17985144      PMCID: PMC2724592          DOI: 10.1007/s00401-007-0313-7

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  51 in total

1.  Risk factors for parkinson's disease: the leisure world cohort study.

Authors:  A Paganini-Hill
Journal:  Neuroepidemiology       Date:  2001-05       Impact factor: 3.282

2.  Progressive loss of cardiac sympathetic innervation in Parkinson's disease.

Authors:  Sheng-Ting Li; Raghuveer Dendi; Courtney Holmes; David S Goldstein
Journal:  Ann Neurol       Date:  2002-08       Impact factor: 10.422

Review 3.  A systematic review of depression and mental illness preceding Parkinson's disease.

Authors:  L Ishihara; C Brayne
Journal:  Acta Neurol Scand       Date:  2006-04       Impact factor: 3.209

4.  Progression of falls in postmortem-confirmed parkinsonian disorders.

Authors:  G K Wenning; G Ebersbach; M Verny; K R Chaudhuri; K Jellinger; A McKee; W Poewe; I Litvan
Journal:  Mov Disord       Date:  1999-11       Impact factor: 10.338

5.  Cardiac sympathetic denervation in Parkinson disease.

Authors:  D S Goldstein; C Holmes; S T Li; S Bruce; L V Metman; R O Cannon
Journal:  Ann Intern Med       Date:  2000-09-05       Impact factor: 25.391

6.  alpha-Synuclein is phosphorylated in synucleinopathy lesions.

Authors:  Hideo Fujiwara; Masato Hasegawa; Naoshi Dohmae; Akiko Kawashima; Eliezer Masliah; Matthew S Goldberg; Jie Shen; Koji Takio; Takeshi Iwatsubo
Journal:  Nat Cell Biol       Date:  2002-02       Impact factor: 28.824

7.  Frequency of bowel movements and the future risk of Parkinson's disease.

Authors:  R D Abbott; H Petrovitch; L R White; K H Masaki; C M Tanner; J D Curb; A Grandinetti; P L Blanchette; J S Popper; G W Ross
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

8.  Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

Authors:  E Bezard; S Dovero; C Prunier; P Ravenscroft; S Chalon; D Guilloteau; A R Crossman; B Bioulac; J M Brotchie; C E Gross
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

9.  Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study.

Authors:  B H Wood; J A Bilclough; A Bowron; R W Walker
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

Review 10.  Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.

Authors:  I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada
Journal:  Neurology       Date:  2005-10-19       Impact factor: 9.910

View more
  42 in total

1.  PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

Authors:  Bin Zheng; Zhixiang Liao; Joseph J Locascio; Kristen A Lesniak; Sarah S Roderick; Marla L Watt; Aron C Eklund; Yanli Zhang-James; Peter D Kim; Michael A Hauser; Edna Grünblatt; Linda B Moran; Silvia A Mandel; Peter Riederer; Renee M Miller; Howard J Federoff; Ullrich Wüllner; Spyridon Papapetropoulos; Moussa B Youdim; Ippolita Cantuti-Castelvetri; Anne B Young; Jeffery M Vance; Richard L Davis; John C Hedreen; Charles H Adler; Thomas G Beach; Manuel B Graeber; Frank A Middleton; Jean-Christophe Rochet; Clemens R Scherzer
Journal:  Sci Transl Med       Date:  2010-10-06       Impact factor: 17.956

2.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.

Authors:  Thomas J Montine; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; John Q Trojanowski; Harry V Vinters; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2011-11-20       Impact factor: 17.088

3.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

Review 4.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

5.  Lewy bodies in essential tremor are no different than in controls.

Authors:  Holly A Shill; Charles H Adler; Thomas G Beach
Journal:  Parkinsonism Relat Disord       Date:  2015-11-24       Impact factor: 4.891

6.  Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders.

Authors:  Thomas G Beach; Charles H Adler; Geidy Serrano; Lucia I Sue; D G Walker; Brittany N Dugger; Holly A Shill; Erika Driver-Dunckley; John N Caviness; Anthony Intorcia; Jessica Filon; Sarah Scott; Angelica Garcia; Brittany Hoffman; Christine M Belden; Kathryn J Davis; Marwan N Sabbagh
Journal:  J Parkinsons Dis       Date:  2016       Impact factor: 5.568

7.  Incidental Lewy body disease: clinical comparison to a control cohort.

Authors:  Charles H Adler; Donald J Connor; Joseph G Hentz; Marwan N Sabbagh; John N Caviness; Holly A Shill; Brie Noble; Thomas G Beach
Journal:  Mov Disord       Date:  2010-04-15       Impact factor: 10.338

8.  Essential tremor and Parkinson's disease: lack of a link.

Authors:  Charles H Adler; Holly A Shill; Thomas G Beach
Journal:  Mov Disord       Date:  2011-01-31       Impact factor: 10.338

9.  Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.

Authors:  Jeffrey H Kordower; C Warren Olanow; Hemraj B Dodiya; Yaping Chu; Thomas G Beach; Charles H Adler; Glenda M Halliday; Raymond T Bartus
Journal:  Brain       Date:  2013-08       Impact factor: 13.501

Review 10.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.